Supernus Pharmaceuticals Inc (SUPN)

Receivables turnover

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Revenue (ttm) US$ in thousands 661,817 654,387 632,578 598,906 607,521 619,414 641,163 674,751 673,056 651,277 618,187 585,808 560,079 545,016 551,524 536,576 506,717 465,383 418,476 402,257
Receivables US$ in thousands 142,077 145,408 152,494 147,734 144,155 141,764 136,556 143,568 165,497 164,086 158,063 145,149 148,932 133,676 137,275 127,065 140,877 133,107 126,559 119,195
Receivables turnover 4.66 4.50 4.15 4.05 4.21 4.37 4.70 4.70 4.07 3.97 3.91 4.04 3.76 4.08 4.02 4.22 3.60 3.50 3.31 3.37

December 31, 2024 calculation

Receivables turnover = Revenue (ttm) ÷ Receivables
= $661,817K ÷ $142,077K
= 4.66

The receivables turnover ratio for Supernus Pharmaceuticals Inc has shown a generally increasing trend over the observed periods from March 31, 2020, to December 31, 2024. This ratio indicates the company's effectiveness in collecting outstanding receivables.

The ratio started at 3.37 on March 31, 2020, and increased to 4.70 by March 31, 2023, showing a significant improvement in collection efficiency. Despite some fluctuations in between, the ratio remained above 4.00 most of the time, which is a positive sign indicating that Supernus Pharmaceuticals Inc is collecting its receivables more frequently.

Overall, the trend suggests that the company has been successful in managing its accounts receivable efficiently and converting them into cash. A higher receivables turnover ratio signifies faster collection of outstanding invoices, which indicates strong liquidity and effective credit management practices within the organization.